EHA 2019 | PRM-151 for myelofibrosis

Srdan Verstovsek

Here, Srdan Verstovsek, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, presents updates on the Phase II study of PRM-151 for myelofibrosis patients previously treated with or are ineligible for treatment with ruxolitinib. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.